

(51) International Patent Classification:

C07D 471/14 (2006.01) A61P 35/00 (2006.01)

C07D 519/00 (2006.01) A61P 35/02 (2006.01)

A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2012/030007

(22) International Filing Date:

21 March 2012 (21.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/466,841 23 March 2011 (23.03.2011) US

(71) Applicant (for all designated States except US): AMGEN

INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHEN, Xiaoqi

[US/US]; 970 Blair Court, Palo Alto, California 94303 (US). DAI, Kang [US/US]; 619 Santa Fe Avenue, Albany, California 94706 (US). DUQUETTE, Jason [US/US]; 1120 Veterans Blvd., South San Francisco, California 94080 (US). GRIBBLE, Michael W., Jr. [US/US]; 949 Capp Street, Apt # 22, San Francisco, California 94110 (US). HUARD, Justin N. [US/US]; 6501 24th Ave NW #202, Seattle, Washington 98117 (US). KEEGAN, Kathleen S. [US/US]; 636 Janelle Pl NW, Bainbridge Island, Washington 98110 (US). LI, Zhihong [US/US]; 467 Anita Drive, Millbrae, California 94030 (US). LIVELY, Sarah E. [GB/US]; 1536 Eaton Avenue, San Carlos, California 94070 (US). MCGEE, Lawrence R. [US/US]; 39 Big Sur Way, Pacifica, California 94044 (US). RAGAINS, Mark

L. [US/US]; 4109 S. Hulen Street, Apt. 312, Fort Worth, Texas 76109 (US). WANG, Xianghong [US/US]; 4915 Shelton Street, Dublin, California 94568 (US). WEIDNER, Margaret F. [US/US]; 15726 160th Ave NE, Woodinville, Washington 98072 (US). ZHANG, Jian [US/US]; 290 Pelican Court, Foster City, California 94404 (US).

(74) Agent: FRIEDRICHSEN, Bernard P.; Amgen Inc., One Amgen Center Drive, Patent Operations MS 28-2-C, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.






(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3



(57) Abstract: Compounds of Formula (I) are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula (I) have the following structure: where R¹ is a group of Formula (IA), Formula (IB), Formula (IC), or Formula (ID) and the definitions of the other variables are provided herein.

WO 2012/129344 A1



Published:

— *with international search report (Art. 21(3))*